Cost Savings and Increased Access With Ultra-Low-Dose Immunotherapy
J Clin Oncol
.
2023 Jan 10;41(2):170-172.
doi: 10.1200/JCO.22.01711.
Epub 2022 Oct 20.
Authors
Aaron P Mitchell
1
,
Daniel A Goldstein
2
3
4
5
Affiliations
1
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
2
Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
3
Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.
4
Clalit Health Service, Tel Aviv-Yafo, Israel.
5
Optimal Cancer Care Alliance, Ann Arbor, MI.
PMID:
36265102
PMCID:
PMC9839306
DOI:
10.1200/JCO.22.01711
No abstract available
Publication types
Editorial
Comment
MeSH terms
Antibodies, Monoclonal*
Cost Savings
Cost-Benefit Analysis
Humans
Immunotherapy*
Substances
Antibodies, Monoclonal
Grants and funding
P30 CA008748/CA/NCI NIH HHS/United States